Teva CEO Steps Down - - BioPharm International

ADVERTISEMENT

Teva CEO Steps Down


Teva Pharmaceutical Industries reported on Oct. 30, 2013 that Jeremy Levin, president and CEO, will step down immediately. Eyal Desheh, Teva's executive vice-pesident and chief financial officer, will fill the role of president and CEO on an interim basis. The company's board of directors has formed a committee that will begin to search for a permanent successor.

The change in leadership at Teva follows a recently announced restructuring program. In October 2013, Teva announced plants to accelerate its restructuring program, which was introduced in December 2012 and included actions to divest noncore assets, increase organization effectiveness, improve manufacturing efficiency, and reduce excess capacity. Teva plans to reduce its global workforce by approximately 10% (approximately 5000 employees) and will complete the majority of the reduction by the end of 2014.

Teva recently reported its third-quarter results. Revenues for the three months ended September 30, 2013 were $5.1 billion, an increase of 2% compared to the third quarter of 2012. In local currency terms, revenues also went up 2%. The increase was primarily attributable to higher sales of generic medicines in the United States, higher revenues from its global specialty and over-the-counter medicines. This increase was partially offset by a decrease in global API sales to third parties.

See related story, "Teva Announces Further Restructuring."

Source: Teva Pharmaceutical Industries (Third-Quarter Results); Teva Pharmaceutical Industries (Executive Change)

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines

Click here